Abstract
Resistance to therapeutic antibodies caused by on-target point mutations is a major obstacle in anticancer therapy, creating an “unmet clinical need.” To tackle this problem, researchers are developing new generations of antibody drugs that can overcome the resistance mechanisms of existing agents. We have previously reported a structure-guided and phage-assisted evolution (SGAPAE) approach to evolve cetuximab, a therapeutic antibody, to effectively reverse the resistance driven by EGFRS492R or EGFRG465R mutations, without changing the binding epitope or compromising the antibody efficacy. In this protocol, we provide detailed instructions on how to use the SGAPAE approach to evolve cetuximab, which can also be applied to other therapeutic antibodies for reversing on-target point mutation-mediated resistance. The protocol consists of four steps: structure preparation, computational prediction, phage display library construction, and antibody candidate selection.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lyu X, Zhao Q, Hui J, Wang T et al (2022) The global landscape of approved antibody therapies. Antib Ther 5(4):233–257
Misale S, Di Nicolantonio F, Sartore-Bianchi A et al (2014) Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 4(11):1269–1280
Schlam I, Tarantino P, Tolaney SM (2022) Overcoming resistance to HER2-directed therapies in breast cancer. Cancers (Basel) 14(16):3996
Torka P, Barth M, Ferdman R et al (2019) Mechanisms of resistance to monoclonal antibodies (mAbs) in lymphoid malignancies. Curr Hematol Malig Rep 14(5):426–438
Arena S, Bellosillo B, Siravegna G et al (2015) Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin Cancer Res 21(9):2157–2166
Montagut C, Dalmases A, Bellosillo B et al (2012) Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat Med 18(2):221–223
Newhall K, Price T, Peeters M et al (2014) Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma dna from metastatic colorectal cancer patients treated with panitumumab or cetuximab monotherapy. Ann Oncol 25:i109
Diwanji D, Trenker R, Thaker TM et al (2021) Structures of the HER2-HER3-NRG1beta complex reveal a dynamic dimer interface. Nature 600(7888):339–343
Shin JW, Kim S, Ha S et al (2019) The HER2 S310F mutant can form an active heterodimer with the EGFR, which can be inhibited by cetuximab but not by trastuzumab as well as pertuzumab. Biomolecules 9(10):629
Arena S, Siravegna G, Mussolin B et al (2016) MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci Transl Med 8(324):314r–324r
Sanchez-Martin FJ, Bellosillo B, Gelabert-Baldrich M et al (2016) The first-in-class anti-EGFR antibody mixture Sym004 overcomes cetuximab resistance mediated by EGFR extracellular domain mutations in colorectal cancer. Clin Cancer Res 22(13):3260–3267
Harb W, Lieu C, Beeram M et al (2014) A first-in-human study evaluating the safety and pharmacology of MM-151, a novel oligoclonal anti-EGFR antibody combination in patients with refractory solid tumors. Ann Oncol 25:v152
Montagut C, Argiles G, Ciardiello F et al (2018) Efficacy of Sym004 in patients with metastatic colorectal cancer with acquired resistance to anti-EGFR therapy and molecularly selected by circulating tumor DNA analyses: a phase 2 randomized clinical trial. JAMA Oncol 4(4):e175245
Zhuang X, Wang Z, Fan J et al (2022) Structure-guided and phage-assisted evolution of a therapeutic anti-EGFR antibody to reverse acquired resistance. Nat Commun 13(1):4431
Fleishman SJ, Leaver-Fay A, Corn JE et al (2011) Rosettascripts: a scripting language interface to the rosetta macromolecular modeling suite. PLoS One 6(6):e20161
Leaver-Fay A, Tyka M, Lewis SM et al (2011) Rosetta3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol 487:545–574
Alfaleh MA, Alsaab HO, Mahmoud AB et al (2020) Phage display derived monoclonal antibodies: from bench to bedside. Front Immunol 11:1986
Ferrari D, Garrapa V, Locatelli M (2020) A novel nanobody scaffold optimized for bacterial expression and suitable for the construction of ribosome display libraries. Mol Biotechnol 62(1):43–55
Frenzel A, Schirrmann T, Hust M (2016) Phage display-derived human antibodies in clinical development and therapy. MAbs 8(7):1177–1194
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Zhuang, X., Chen, S., Pan, L. (2024). Structure-Guided and Phage-Assisted Evolution of Therapeutic Antibodies to Reverse On-Target Point Mutation-Mediated Resistance. In: Peng, H., Liu, J., Chen, I.A. (eds) Phage Engineering and Analysis. Methods in Molecular Biology, vol 2793. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3798-2_3
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3798-2_3
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3797-5
Online ISBN: 978-1-0716-3798-2
eBook Packages: Springer Protocols